论文部分内容阅读
目的 :探讨抗卵巢癌细胞膜抗体作为放射免疫治疗载体的可能性 ,及对靶细胞体外裸鼠体内杀伤的相对特异性。方法 :采用补体介导细胞毒性试验 (MTT法 )测定抗卵巢癌细胞膜抗体对靶、非靶细胞比毒性 ;建立 BAL B/ C- m u裸鼠荷人卵巢癌模型 ,用 SPECT显像及病理检查分析 1 31 I标记抗卵巢癌细胞膜抗体在荷人卵巢癌裸鼠的聚集性。结果 :抗卵巢癌细胞膜纯化抗体比抗血清对卵巢癌靶细胞显示了更强的细胞毒作用 ,并且都显示了浓度梯度依赖性。抗卵巢癌细胞膜抗体对靶、非靶细胞比毒性显示了相对特异性 ,对卵巢癌细胞杀伤率高于非靶细胞 (宫颈癌、肝癌、胃癌、O型白细胞 )。并且呈时间依赖关系。1 31 I标记抗卵巢癌细胞膜抗体对荷人卵巢癌裸鼠腹腔注射 3d后 ,肿瘤区即有明显聚集 ,一直持续至第 8天。注射后第 8天 ,行病理检查 ,肉眼见有局部坏死淤血区 ;镜下见癌区组织大片状坏死 ,坏死区可见淋巴细胞浸润。结论 :抗卵巢癌细胞膜抗体对体内、体外卵巢癌细胞有相对特异性靶向性 ,具有作为放射免疫治疗载体的能力
OBJECTIVE: To investigate the possibility of anti-ovarian cancer cell membrane antibodies as radioimmunotherapy carriers and the relative specificity of anti-ovarian cancer cell membrane anti-tumor targets in vitro in nude mice. Methods: The cytotoxicity of anti-ovarian cancer cell membrane against target and non-target cells was determined by complement-mediated cytotoxicity assay (MTT). BALB / C-nude human ovarian cancer model was established. SPECT imaging and pathological examination Analysis of 1 31 I labeled anti-ovarian cancer cell membrane antibody in nude mice bearing ovarian cancer aggregation. RESULTS: Anti-ovarian cancer cell membrane-purified antibodies showed more cytotoxic effects on ovarian cancer target cells than antisera and both showed a concentration-gradient dependence. Anti-ovarian cancer cell membrane antibodies on the target, non-target cells showed relatively specific toxicity, ovarian cancer cell killing rate higher than non-target cells (cervical cancer, liver cancer, gastric cancer, O-type leukocytes). And in a time-dependent manner. 1 31 I labeled anti-ovarian cancer cell membrane antibody in human ovarian cancer nude mice injected 3d after intraperitoneal injection, the tumor area that was significantly aggregated, until the first 8 days. On the 8th day after injection, the pathological examination was performed, and the local necrosis was found in the naked eye. In the microscopic section, massive necrosis of the cancerous tissue was observed. Lymphocyte infiltration was observed in the necrotic area. CONCLUSIONS: Anti-ovarian cancer cell membrane antibodies have relatively specific targeting to in vitro and in vivo ovarian cancer cells and have the potential of being carriers of radioimmunotherapy